Class will soon be in session at the Allergan Aesthetics headquarters. The AbbVie brand plans to open doors at its ...

Brin's been researching Botox since 1984 and is currently the chief scientific officer of Botox at the drug company Allergan. It's one of many Botox-related license plates he owns, including some ...

Allergan is still on the acquisition trail following its failed merger with Pfizer, spending $85 million to acquire privately-held Topokine Therapeutics and its late-stage product for under-eye bags.

Allergan has bought the privately-held biotech Bonti, which has been developing a fast-acting, short duration replacement alternative to Botox ahead of potentially cheaper competition from a ...

The Food and Drug Administration announced Monday it has approved a product called Botox Cosmetic to treat moderate to severe frown lines between the eyebrows. Botox is made from the toxin that causes ...

Instead of filing multiple applications claiming different aspects of an invention but not sharing a single priority ...

This article was originally published on April 22 and has been updated. Allergan CEO Brent Saunders, $6,624,473 Brent Saunders has been presiding over Allergan and its billion-dollar Botox empire ...

It was then that Actavis, a drug company that specializes in generic drugs and over-the-counter products, scooped up Allergan for a neat $66 billion. Here's a photo of Actavis CEO Brenton Saunders ...

Patel had spent more than a decade working at Allergan, setting up the Botox-makers' presence in Russia, South Africa, Poland, and Turkey. At that point, Allergan was a small Southern California ...

AbbVie's diversified portfolio, including drugs from the 2019 Allergan acquisition, continues to mitigate revenue declines from Humira's patent expiration. Risks include Medicare pricing changes ...

Class will soon be in session at the Allergan Aesthetics headquarters. The AbbVie brand plans to open doors at its headquarters in Irvine, Calif., to offer an immersive training center for health ...